What is Bristol-Myers Squibb Company's (BMY) StockRank?

MoatMap's StockRank for Bristol-Myers Squibb Company (BMY) is 98/100, with a Strong Buy signal. This is a composite score combining Quality (75), Value (64), and Momentum (73) factor ranks across MoatMap's 20,000+ stock universe.

Does Bristol-Myers Squibb Company have an economic moat?

Bristol-Myers Squibb Company (BMY) has a Quality factor score of 75/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Bristol-Myers Squibb Company a buy, hold, or sell?

MoatMap's current signal for Bristol-Myers Squibb Company (BMY) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Bristol-Myers Squibb Company in?

Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (United States).

Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

BMY

Strong BuyFull HouseAPPROVE

Bristol-Myers Squibb Company · Healthcare · United States · $136.0B · Avg Vol: $709M/d

StockRank

Get insider-trade alerts

P/E (TTM)

14.7x

ROE

46.6%

D/E

2.0x

Dividend %

3.7%

AI CONVICTION THESIS

Passes all quantitative thresholds and exhibits a neutral to clean regulatory signal. Its stable profile fits the criteria for quality compounding in a high-conviction pharmaceutical portfolio.

COMPANY DESCRIPTION

Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines for serious diseases, primarily in oncology, immunology, cardiovascular, and hematology. Its strong research and development pipeline, coupled with a portfolio of blockbuster drugs and strategic acquisitions, provides a significant competitive moat in specialized therapeutic areas. BMY is a leading global biopharmaceutical firm known for its groundbreaking therapies and robust intellectual property portfolio.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	46.2B	45.0B	48.3B	48.2B	1.4%	49.2B	49.8B	48.1B	-0.1%
EPS	2.97	3.88	-4.41	3.47	5.3%	4.54	3.92	3.70	3.3%
Shares	2.1B	2.0B	2.0B	2.0B	-1.9%	2.0B	—	—	—
Debt	40.7B	41.5B	51.2B	47.1B	5.0%	45.1B	—	—	—
Equity	31.1B	29.4B	16.3B	18.5B	-15.9%	—	—	—	—
Op CF	13.1B	13.9B	15.2B	14.2B	2.7%	12.8B	—	—	—
Inv CF	-1.1B	-2.3B	-21.4B	-4.1B	—	—	—	—	—
Fin CF	-17.0B	-9.4B	5.1B	-10.3B	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+6.8%

SMA 50SMA 200

$66.82

RSI (14)

59.4

52W High

$68.64

From 52W High

1.0%

SCORE BREAKDOWN

Quality

ROIC

16.8%88.7

ROE

46.6%97.4

GP/Assets

39.1%77.7

Op. Margin

34.4%94.2

FCF/Assets

10.9%88.7

Piotroski

894.4

Int. Cover

5.9x56.0

D/E Ratio

2.02x5.6

Current Ratio

1.53x26.7

Value

P/E (TTM)

14.7x72.1

EV/EBITDA

9.0x71.9

P/FCF

13.8x73.7

P/B

6.1x21.4

P/S

2.8x58.6

Div Yield

3.7%78.6

Momentum

52W High %

97%97.1

RS 6M

-2%64.6

SMA 50/200

1.10x76.7

EPS Rev 4W

+0.5%44.0

EPS Rev 12W

+6.3%81.8

EPS Improve

+44%51.4

Q Growth

153%88.7

FUNDAMENTALS

Market Cap

$136.0B

P/E (Forward)

10.2x

Gross Margin

71.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BMY are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
BMY	Bristol-Myers Squibb Company(you)	$136.0B	98	Strong Buy
SNY	Sanofi	$107.4B	96	Strong Buy
G1SK34.SA	GSK plc	$101.2B	93	Strong Buy
N1VO34.SA	Novo Nordisk A/S	$201.0B	95	Strong Buy
PFE	Pfizer Inc.	$159.4B	89	Strong Buy
AMGN	Amgen Inc.	$233.8B	89	Strong Buy
NOVN.SW	Novartis AG	$290.6B	86	Strong Buy
GILD	Gilead Sciences, Inc.	$180.6B	76	Buy
4578.T	Otsuka Holdings Co., Ltd.	$40.0B	95	Strong Buy
ROP.SW	Roche Holding AG	$353.1B	87	Strong Buy

Peer medians: ROE 1.6% · P/E 23.2x · Gross margin 52.3%

Bristol-Myers Squibb Company (BMY): Stock Score Summary

Bristol-Myers Squibb Company (BMY) has a MoatMap StockRank of 98/100 based on Quality (75/100), Value (64/100), and Momentum (73/100) factor scores. The current signal is STRONG BUY. Passes all quantitative thresholds and exhibits a neutral to clean regulatory signal. Its stable profile fits the criteria for quality compounding in a high-conviction pharmaceutical portfolio.

Key Financial Metrics

Price	$66.82
Market Cap	$136.0B
P/E (TTM)	14.72
P/E (Forward)	10.19
Price/Book	6.12
Return on Equity	46.6%
Return on Invested Capital	16.8%
Debt/Equity	2.02x
Gross Margin	71.7%
Operating Margin	34.4%
Revenue Growth	5.7%
Dividend Yield	3.7%
Free Cash Flow	$9.9B

Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Bristol-Myers Squibb Company’s (BMY) StockRank?: MoatMap’s StockRank for Bristol-Myers Squibb Company (BMY) is 98/100, with a Strong Buy signal. It is a composite of Quality (75), Value (64), and Momentum (73) factor ranks across MoatMap’s 20,000+ stock universe.
Does Bristol-Myers Squibb Company have an economic moat?: Bristol-Myers Squibb Company (BMY) has a Quality factor score of 75/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Bristol-Myers Squibb Company a buy, hold, or sell?: MoatMap’s current signal for Bristol-Myers Squibb Company (BMY) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Bristol-Myers Squibb Company in?: Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (United States).